The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Yazar
Arslan, Cagatay
Yekeduz, Emre
Tural, Deniz
Erturk, Ismail
Karakaya, Serdar
EROL, CİHAN
Ercelep, Ozlem
Sever, Ozlem Nuray
ÜRÜN, YÜKSEL
Karadurmus, Nuri
ŞENDUR, MEHMET ALİ NAHİT
Oksuzoglu, Berna
Can, Orcun
Kucukarda, Ahmet
Senturk Oztas, Nihan
KILIÇKAP, SAADETTİN
Üst veri
Tüm öğe kaydını göster
Özet
Background Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.
Bağlantı
http://hdl.handle.net/20.500.12627/184183
https://avesis.istanbul.edu.tr/api/publication/aba155b8-6686-4b3a-81fb-c3b41fa0ab10/file
https://doi.org/10.1007/s00432-022-04055-5
Koleksiyonlar